litlas
Log inCreate account

Mario Mandalà

Active 1999–2025

Also published as
Mario Mandala
177
Papers
37,258
Citations
80
h-index
168
i10-index

Citations

Citations per year for Mario Mandalà1967: 2 citations1989: 1 citations2001: 2 citations2002: 10 citations2003: 9 citations2004: 6 citations2005: 8 citations2006: 10 citations2007: 12 citations2008: 9 citations2009: 16 citations2010: 15 citations2011: 34 citations2012: 56 citations2013: 46 citations2014: 74 citations2015: 251 citations2016: 259 citations2017: 354 citations2018: 454 citations2019: 1,840 citations2020: 2,089 citations2021: 2,155 citations2022: 1,781 citations2023: 1,329 citations2024: 2,099 citations2025: 886 citations2026: 14 citations1968–1988: no citations, so these years are not shown1990–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,999 citing papers, 20.4% of this breakdownChina: 1,684 citing papers, 11.5% of this breakdownItaly: 1,113 citing papers, 7.6% of this breakdownGermany: 845 citing papers, 5.7% of this breakdownUnited Kingdom: 833 citing papers, 5.7% of this breakdownFrance: 729 citing papers, 5% of this breakdownAustralia: 611 citing papers, 4.1% of this breakdownNetherlands: 571 citing papers, 3.9% of this breakdownJapan: 499 citing papers, 3.4% of this breakdownCanada: 474 citing papers, 3.2% of this breakdownSpain: 474 citing papers, 3.2% of this breakdownSwitzerland: 391 citing papers, 2.7% of this breakdown
0%20.4%Other 23.6%

Institutions

Fields

  • Medicine67.4%
  • Biochemistry, Genetics and Molecular Biology23.8%
  • Immunology and Microbiology4.1%
  • Neuroscience1.1%
  • Computer Science0.6%
  • Health Professions0.6%
  • Other2.4%

Topics

  • Cancer Immunotherapy and Biomarkers12.8%
  • Melanoma and MAPK Pathways7.2%
  • Cutaneous Melanoma Detection and Management5%
  • Immunotherapy and Immune Responses4.4%
  • CAR-T cell therapy research3.7%
  • Gastric Cancer Management and Outcomes2.4%
  • Other64.5%

Coauthors

All papers

Open in search
  1. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    Authors: Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I. Jalal, Manish A. Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandalà, Zev A. Wainberg, Daniel V.T. Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip Philip, Peter C. Enzinger, Yung‐Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon - JAMA Oncology 2018 cited by 1,812

  2. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Authors: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 cited by 2,207

  3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 cited by 1,853

  4. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    Authors: Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Maćkiewicz, Piotr Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V. Long - New England Journal of Medicine 2019 cited by 1,376

  5. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Roberto Labianca, Bernard Nordlinger, Giordano Beretta, Stefania Mosconi, Mario Mandalà, Andrés Cervantes, Dirk Arnold - Annals of Oncology 2013 cited by 1,421

  6. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

    Authors: Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendorf, Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Vernon K Sondak, Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Alexander M M Eggermont - The Lancet 2022 cited by 477

  7. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Authors: Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham‐Shmueli, Xinqun Chen, Carlos Mayo, Soonmo Peter Kang, Atsushi Ohtsu, Charles S. Fuchs, Guillermo Lerzo, Juan Manuel O’Connor, Guillermo Ariel Mendez, James Lynam, Niall C. Tebbutt, Mark Wong, Andrew Strickland, Christos S. Karapetis, David Goldstein, Paul L. Vasey, Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316

  8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Authors: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 cited by 1,016

  9. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 cited by 1,871

  10. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

    Authors: Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood - New England Journal of Medicine 2017 cited by 1,475

  11. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

    Authors: James Larkin, Paolo A. Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Caroline Dutriaux, Claus Garbe, Mika A. Sovak, Ilsung Chang, Nicholas W. Choong, Stephen P. Hack, Grant A. McArthur, Antoni Ribas - New England Journal of Medicine 2014 cited by 2,032

  12. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Authors: Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Célèste Lebbé, Hildur Helgadóttir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio Maria Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion‐Sileni - Journal of Clinical Oncology 2022 cited by 220

  13. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Authors: Anna Falanga, Cihan Ay, Marcello Di Nisio, Grigoris Gerotziafas, Luis Jara‐Palomares, F. Langer, Ramón Lecumberri, Mario Mandalà, Anthony Maraveyas, I. Pabinger, M. Sinn, K. Syrigos, Annie Young, Karin Jordan - Annals of Oncology 2023 cited by 384

  14. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    Authors: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 cited by 525

  15. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 cited by 1,386

  16. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    Authors: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 cited by 180

  17. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

    Authors: Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, L. Thomas, Luis de la Cruz‐Merino, Caroline Dutriaux, Claus Garbe, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Jessie J. Hsu, Daniel O. Koralek, Isabelle Rooney, Antoni Ribas, James Larkin - The Lancet Oncology 2016 cited by 1,005

  18. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  19. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Caroline Robert, Stefan Suciu - JAMA Oncology 2020 cited by 436

  20. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

    Authors: Jake S. O’Donnell, Daniela Massi, Michele W.L. Teng, Mario Mandalà - Seminars in Cancer Biology 2017 cited by 367

  21. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma

    Authors: Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo A. Ascierto - Journal of Clinical Oncology 2022 cited by 185

  22. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Krepler, Sandrine Marréaud, Stefan Suciu, Caroline Robert - NEJM Evidence 2022 cited by 150

  23. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Authors: Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M. Kirkwood, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V. Long, Dirk Schadendorf - New England Journal of Medicine 2020 cited by 407

  24. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - Journal of Clinical Oncology 2022 cited by 163